In 2026, biological products continue to expand across U.S. agriculture, but a persistent trust gap among growers and ag retailers is slowing full-scale adoption, despite strong market growth and increased investment from major agribusiness companies. Surveys and industry feedback show that while biologicals are widely available and increasingly integrated into crop programs, many growers remain cautious due to inconsistent performance, uncertain return on investment, and limited long-term field validation. This matters because biologicals are positioned as a key tool for sustainable agriculture, yet their success depends on confidence at the farm level, where input decisions directly impact yields and profitability .

The most significant factor behind grower skepticism is lack of confidence in product performance under real-world conditions. While biologicals often demonstrate positive results in controlled trials, variability across soil types, weather patterns, and management systems continues to create uncertainty.

Barriers to Biological Adoption in U.S. Agriculture

This data highlights that trust-not availability-is the main constraint, with nearly four out of ten industry participants identifying it as the leading obstacle.

Biologicals still seen as complementary, not core inputs

Another key factor contributing to skepticism is how biologicals are currently used in the field. The overwhelming majority of growers apply them alongside conventional fertilizers and crop protection products, rather than as stand-alone solutions.

Bioinputs

Biological Inputs: The Fight for Profitability Is Reshaping Agriculture in Latin America

How Growers Use Biological Products

This pattern reinforces the perception that biologicals are risk-management tools rather than primary yield drivers, particularly in large-scale row crop systems like corn and soybeans.

Retailers play a key role in bridging the gap

Ag retailers and co-ops are at the center of biological adoption, acting as the primary interface between product innovation and on-farm application. However, their recommendations depend heavily on clear data, consistent performance, and ease of integration into existing programs.

Retailers report that growers are increasingly asking not whether biologicals work, but how they compare to traditional inputs and where they fit within a program. This shift reflects a more mature market, but also raises the bar for product validation and technical support.

Trust-Building Factors in Biological Adoption

Efforts to improve transparency include certification programs, expanded field trials, and more rigorous product positioning. These initiatives are designed to reduce variability and provide growers with clearer expectations of performance.

Economic pressure amplifies skepticism

The current economic environment is also shaping grower attitudes. With commodity prices under pressure and input costs remaining elevated, producers are prioritizing investments that deliver predictable returns.

Biologicals, while promising, often compete with well-established conventional products that offer proven and consistent performance. As a result, growers are less willing to take risks, particularly in large-acre operations where small performance differences can translate into significant financial outcomes.

At the same time, biologicals are gaining traction in specific use cases, such as early-season stress management, soil health improvement, and nutrient efficiency enhancement, where their value is more clearly defined.

Closing the gap requires data and consistency

Industry stakeholders increasingly recognize that overcoming skepticism will depend on delivering consistent, repeatable results across diverse environments. This includes improving formulation quality, refining application recommendations, and expanding field-level data.

As biologicals continue to evolve, their role is expected to grow, but only if they can demonstrate reliable performance that aligns with the economic realities of modern U.S. farming systems.